Abstract Aims To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and ...

European Heart Journal, Filippatos, Gerasimos, Anker, Stefan D., Böhm, Michael, Gheorghiade, Mihai, Køber, Lars, Krum, Henry, Maggioni, Aldo P., Ponikowski, Piotr, Voors, Adriaan A., Zannad, ...

Abstract Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HFREF), and mild-to-severe symptoms, and in ...

European Heart Journal, Zannad, Faiez, Gattis Stough, Wendy, Rossignol, Patrick, Bauersachs, Johann, McMurray, John J.V., Swedberg, Karl, Struthers, Allan D., Voors, Adriaan A., Ruilope, Luis M., ...

Abstract Aims To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and ...

European Heart Journal, Filippatos, Gerasimos, Anker, Stefan D., Böhm, Michael, Gheorghiade, Mihai, Køber, Lars, Krum, Henry, Maggioni, Aldo P., Ponikowski, Piotr, Voors, Adriaan A., Zannad, ...